A5041419953- Rheumatoid Arthritis Research and Therapies
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Mechanical Circulatory Support Devices
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Hepatitis C virus research
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Bone health and treatments
- Liver Disease Diagnosis and Treatment
- Infective Endocarditis Diagnosis and Management
- Cardiac Arrest and Resuscitation
- Cardiovascular Effects of Exercise
- Lymphoma Diagnosis and Treatment
- Cardiovascular Disease and Adiposity
- Bone health and osteoporosis research
- Hepatitis B Virus Studies
- Bone and Joint Diseases
- Cardiovascular Function and Risk Factors
- Antiplatelet Therapy and Cardiovascular Diseases
- Spondyloarthritis Studies and Treatments
Sorbonne Université
2018-2024
Pitié-Salpêtrière Hospital
2020-2024
Inserm
2012-2023
Assistance Publique – Hôpitaux de Paris
2012-2023
Laboratoire de Statistique Théorique et Appliquée
2023
Université Claude Bernard Lyon 1
2022
Roche (France)
2007-2021
Fondation pour l’innovation en Cadiométabolisme et Nutrition
2021
Action Contre la Faim
2020
Centre Hospitalier Universitaire Amiens-Picardie
2019
AimsThe ESC/ACC redefined myocardial infarction as any amount of necrosis caused by ischaemia. The aim this study was to describe the management and outcomes using 'real-world' data taking new definition acute into account.
Abstract Objective To examine whether serum B cell markers can predict response to rituximab, a cell–depleting monoclonal antibody, in patients with refractory rheumatoid arthritis (RA). Methods This rituximab re‐treatment dose study (SMART [eSsai MAbthera sur la de Re‐Traitement]) involved 208 RA. Serum of activation (anti–cyclic citrullinated peptide [anti‐CCP] antibodies, factor [RF], IgG, IgA, and IgM levels, κ λ free light chains, BAFF) were assessed before the first cycle (1,000 mg on...
To examine blood B cell subsets in patients with rheumatoid arthritis (RA) prior to depletion therapy and assess their potential as predictors of clinical response rituximab (RTX).Blood were assessed by flow cytometry 208 RA included an RTX retreatment study (assessed treatment) 47 age-matched controls. Expression BAFF receptor (BAFF-R) on cells serum biomarkers was also measured. BAFF-R expression compared between patient control populations. Univariate multivariate analyses performed...
<h3>Objective</h3> To assess the association between a single nucleotide polymorphism in gene of <i>FCGR3A</i> and response to treatment with rituximab (RTX) rheumatoid arthritis (RA). <h3>Methods</h3> SMART is randomised open trial assessing two strategies re-treatment patients responding 1 g infusion RTX methotrexate on days 15 after failure, intolerance or contraindication tumour necrosis factor (TNF) blockers. Among 224 included, 111 could be genotyped were included an ancillary study...
<h3>Background</h3> The licensed dose of rituximab in rheumatoid arthritis (RA) is two doses 1000 mg given 2 weeks apart. A lower has never been specifically studied patients with an inadequate response to anti-tumour necrosis factor (TNF) agents. <h3>Objective</h3> To compare the efficacy and safety repeat treatment (1000 mg×1 mg×2) following initial mg×2. <h3>Methods</h3> We set up open-label, prospective, multicentre, non-inferiority study comprising a non-controlled period (24 weeks)...
Objective To identify a molecular signature that could be predictive of the clinical response to rituximab (RTX) and elucidate transcriptomic changes after RTX therapy in patients with rheumatoid arthritis (RA), use whole‐blood profiling. Methods A microarray assay whole human genome was performed using RNA from peripheral blood samples obtained before first cycle 68 RA SMART study. The profile also assessed 24 weeks administration (among nonresponders 44 responders, according European...
Abstract Aims Epicardial adipose tissue (EAT) could contribute to the specific atherosclerosis profile observed in premature coronary artery disease (pCAD) characterized by accelerated plaque burden (calcified and non-calcified), high-risk (HRP) features, ischaemic recurrence. Our aims were describe EAT volume density pCAD compared with asymptomatic individuals matched on cardiovascular risk factors study their relationship severity extension vulnerability. Methods results Two hundred eight...
Abstract Background There are currently no data regarding pre-treatment with P2Y12 inhibitors in patients acute myocardial infarction complicated cardiogenic shock (AMI-CS). This study investigates the effectiveness and safety of AMI-CS. Methods Results Using ACTION-SHOCK cohort, we included consecutive hospitalized between 2012 2023 AMI-CS admitted for coronary angiography within 24 hours admission. Pre-treatment was defined by administration before an oral loading dose a inhibitor. We...
Background Topical nonsteroidal anti-inflammatory drugs offer the advantage of enhanced drug delivery to local affected tissues with low plasma levels and an expected reduced incidence systemic adverse events (mainly peptic ulcer disease gastrointestinal hemorrhage). Hypothesis To test efficacy tolerability a 100-mg patch ketoprofen applied once day. Study Design Randomized controlled clinical trial; Level evidence, 1. Methods The 2-week trial included patients suffering painful (spontaneous...
Migration of B cells from peripheral blood to the synovium in patients with rheumatoid arthritis (RA) may predict clinical response rituximab (RTX). We undertook this study investigate whether serum levels chemokines involved cell trafficking are correlated memory or activation biomarkers before depletion and chemokine RTX responsiveness.Blood subsets were analyzed by flow cytometry (CD27, IgD), (rheumatoid factor, anti-cyclic citrullinated peptide, free light chains, IgG, IgA, IgM, BAFF)...
Objectives: Maternal age has been increasing for several decades with many of these late pregnancies between 40 and 45 years old. This is explained by the societal evolution marked a constantly use controlled contraception. Late marriage second marriages are also becoming more frequent. The main objective this study to assess whether maternal an independent factor obstetric, fetal neonatal complications. Patients methods: A monocentric, French "exposed-unexposed" was conducted during 11 in...
Objective. To determine whether a functional single-nucleotide polymorphism in the B-cell activating factor (BAFF) gene correlates with response to treatment rituximab (RTX) RA. Methods. SMART is randomized open trial (NCT01126541) assessing two strategies of re-treatment patients responding 1-g infusion RTX MTX on days 1 and 15 after failure, intolerance or contraindication TNF blockers. Among 224 included, 115 provided informed consent, could be genotyped were included an ancillary study...
Objective. For optimal RA management, the current recommendation is to adapt DMARD therapy level of inflammation and not only patient complaints. We designed DUO (epidemiological study treatment decison in RA: DROs PROs) assess relative weight patient-reported outcomes (PROs) doctor-reported (DROs) intensification patients. Methods. This French, observational, multicentre, cross-sectional was conducted 2009 on patients included by rheumatologists. The percentage with evaluated regard...
To investigate maintenance of rituximab (RTX) in RA patients re-treated with reduced doses compared standard dose a real life setting. The Autoimmunity and Rituximab (AIR) registry is nationwide prospective observational cohort investigating the long-term safety efficacy RTX RA. present study included from AIR that have been after first course (1000 mg × 2). Two groups were defined according to retreatment (i.e. second course): group group. Five years' rate serious infections period between...